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egulation of cellular proliferation constitutes one of the
undamental mechanisms of biology. In the context of
ardiovascular disease, imbalances in the delicate equilib-
ium between cell proliferation and programmed cell death
lay a role in diseases such as in-stent restenosis (1), left
entricular remodeling (2), cardiac allograft vasculopathy
3), and, importantly, atherosclerosis (4).
See page 2258
Cell-cycle regulation is complex and involves numerous
ndogenous factors that can positively or negatively interfere
ith cell-cycle progression. Cell-cycle progression is gov-
rned by the temporarily coordinated synthesis, activation,
nhibition, and degradation of distinct families of regulatory
roteins (5). Cyclins and cyclin-dependent kinases (CDKs)
orm stable complexes in their active states and function as
ositive regulators of the cell cycle. The phase-specific
ctivation of distinct cyclin/CDK complexes regulates pro-
ression through the cell cycle. Cyclin/CDK activities are
ssociated with cyclin levels as well as CDK phosphoryla-
ion status. Different members of the CDK family, in
ssociation with different cyclins, turn key switches
hroughout the cell cycle; other family members regulate
ranscription, differentiation, nutrient uptake, and other
unctions. Cyclin-dependent kinase inhibitors (CKIs) are
egative regulators of the cell cycle (6).
CKIs are comprised of 2 major families: the CIP/KIP
amily includes p21CIP1, p27KIP1, and p57KIP2, whereas the
NK4 family includes p15INK4B, p16INK4A, p18INK4C, and
19INK4D. p27KIP1 is a major therapeutic target to prevent
estenosis by means of drug-eluting stents since, for exam-
le, sirolimus, the drug released from the Cypher stent
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From the Department of Cardiology and Angiology, Evangelisches Bethesda-
ohanniter-Klinikum, Duisburg, Germany.latform (Cordis, Bridgewater, New Jersey), inhibits the
ammalian target of rapamycin (mTOR) that initiates a
athway that leads to p27KIP1 degradation upon mitogenic
ctivation (7). Therefore, sirolimus interacts positively with
ost-transcriptional levels of p27KIP1 and thus induces early
ell-cycle arrest in the G1 phase, which resembles the major
ffect for inhibition of smooth muscle cell proliferation and
estenosis.
In this issue of the Journal, Gonza´lez-Navarro et al. (8)
nravel an as yet undefined role of p19ARF in mice deficient
n this particular gene and additionally lacking apolipopro-
ein E (apoE), an established mouse model of atheroscle-
osis. Besides p16INK4A, the CDKN2A gene locus on
hromosome 9 encodes a second open reading frame (ARF:
lternative reading frame) that encodes for a 14-kDa protein
n humans (p14ARF) or a 19-kDa protein in mice (p19ARF)
Fig. 1A). In meticulously performed experiments, the
uthors are able to establish a protective role for p19ARF in
he pathogenesis of atherosclerosis. This is mainly mediated
y a pro-apoptotic effect of p19ARF on macrophages and
ascular smooth muscle cells within atherosclerotic lesions.
herefore, p19ARF deficiency leads to augmentation of
therosclerosis independent of lipoprotein levels or prolif-
rative plaque activity. The latter is an unexpected finding
ince p19ARF functions as a negative regulator of prolifera-
ion. However, the authors found that p16INK4A can com-
ensate for missing p19ARF activity, notably demonstrating
redundancy of biological function for these proteins
ncoded by the CDKN2A gene. A further important finding
f the study is that the pro-atherosclerotic phenotype could
xclusively be observed in regions highly prone to athero-
clerotic lesion development, suggesting, as the authors
oint out correctly, that p19ARF is less involved in the
nitiation than in the progression of lesion development.
The findings of Gonza´lez-Navarro et al. (8) add further to
he scientific mosaic of the complex pathogenesis of athero-
clerosis, which is a complicated interplay between genetics,
nflammation, apoptosis, proliferation, and senescence. It ap-
ears that CKIs are regulators of and important linkers
etween these pathophysiological key processes. This is under-
cored by numerous observations that loss of tumor suppressor
roteins, such as members of the CIP/KIP family including
27KIP (9) as well as p53 (10) or retinoblastoma protein (11) in
ene-targeted animal models, are associated with acceleration
f atherosclerotic lesion formation.
Recently, several genome-wide association studies re-
ealed that the chromosome locus 9p21.3 is associated with
therosclerosis (12,13). This locus, which is in close prox-
mity to the genes CDKN2A (encoding for p16INK4A and
19ARF in mice or p14ARF in man) and CDKN2B (encoding
or p15INK4B), spans 58 kb and encompasses multiple single
ucleotide polymorphisms (SNPs) in tight linkage disequi-
ibrium. The biological functions of the CDKN2A gene
roducts are depicted in Figure 1A. Approximately 25% of
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pproximately 1.5-fold increased risk for coronary artery dis-
ase (13). The increased risk is independent of typical athero-
clerotic risk factors such as plasma lipids, hypertension, dia-
etes, obesity, and markers of inflammation. The findings
resented in the current study by Gonza´lez-Navarro et al. (8)
dd to the emerging evidence of a pathophysiological link of
Figure 1
Role of the CDKN2A Gene and CKIs
in Key Pathophysiological Processes
Associated With Atherosclerotic Lesion Formation
(A) Schematic depiction of the interaction of the gene products of the CDKN2A
gene, p19ARF (in man: p14ARF), and p16INK4A with various molecules associ-
ated with cell-cycle regulation and apoptosis. The cyclin-dependent kinase
inhibitor (CKI) p16INK4A induces cell-cycle arrest via inhibition of CDK-4 and -6
that associate with D-type cyclins to subsequently phosphorylate Rb, thereby
facilitating the dissociation of E2F that ultimately leads to entry into the cell
cycle. p19ARF inhibits MDM2, an important negative regulator of the tumor sup-
pressor p53 that can induce the CKI p21CIP1, which subsequently inhibits
important G1/S CDKs such as CDK-2, -4, and -6. p53 is also a potent inducer
of apoptosis. MDM2 functions both as an E3 ubiquitin ligase as well as an inhibi-
tor of p53 transcriptional activation. (B) Illustration of the complex interaction of
CDK inhibitors with major pathophysiological mechanisms of atherosclerosis.
CDK  cyclin-dependent kinase; Rb  retinoblastoma protein; Ub  ubiquitin.enomic susceptibility to an atherosclerotic phenotype.Atherosclerosis is considered to be initiated by inflam-
atory mechanisms (14). However, in early as well as in
dvanced lesions, vascular proliferation does play a pivotal
ole in disease progression (4). CKIs can systemically and
ocally inhibit both inflammatory (15) as well as proliferative
rocesses (16), predominantly by cell-cycle inhibition
nd/or the induction of apoptosis in various cell types such
s macrophages or vascular smooth muscle cells. Therefore,
ovel therapeutic concepts might take advantage of these
leiotropic CKI effects. In this context, it is interesting to
cknowledge that even acute therapeutic CKI induction has
een associated with a sizable therapeutic effect in experi-
ental stroke (17).
Human atherosclerosis is also associated with aging.
herefore, it is characterized by senescence of vascular
mooth muscle cells, inhibition of telomerase, and telomere
hortening (18). Although Gonza´lez-Navarro et al. (8)
ould not find evidence of senescence in the model of
19ARF/apoE-deficient mice, it has been consistently shown
hat p16INK4A is up-regulated in senescent human athero-
clerotic lesions (18). Inhibition of p38 MAP kinase can
lock the induction of p16INK4A and cellular senescence in
roliferative endothelial progenitor cells (EPCs) (19). Noth-
ng is known so far about the effect of p19ARF on cellular
enescence in atherosclerosis; however, studies in bone-
arrow-derived pre–B cells and macrophages suggest that
19ARF can oppose the pro-senescent effects of p16INK4A (20).
In summary, CKIs are increasingly recognized as linking
lements among genetic susceptibility, inflammation, pro-
iferation, apoptosis, and senescence in atherosclerosis (Fig.
B). Their careful evaluation, albeit still at an early stage,
ill possibly enable the identification of novel treatment
pportunities to combat one of the most relevant diseases of
odern times.
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